Edema

:This page is about the medical condition. For the rock band, see Adema.Edema , oedema or Å“dema , formerly known as dropsy or hydropsy, is the increase of interstitial fluid in any organ — swelling. Generally, the amount of interstitial fluid is in the balance of homeostasis. Increased secretion of fluid into the interstitium or impaired removal of this fluid may cause edema. Generation of interstitial fluid is regulated by the Starling equation of tissue fluid which states that it depends on the balance of osmotic pressure and of hydrostatic pressure which act in opposite directions across the semipermeable capillary walls. Consequently, anything that increases oncotic pressure outside blood vessels , or reduces oncotic pressure in the blood will cause edema. Increased hydrostatic pressure inside the blood vessel will have the same effect. If the permeability of the capillary walls increases, more fluid will tend to escape out of the capillary, as can happen when there is inflammation.Abnormal removal of interstitial fluid is caused by obstruction of the lymphatic system, for example due to pressure from a cancer or enlarged lymph nodes, destruction of lymph vessels by radiotherapy, or infiltration of the lymphatics by infection such as elephantiasis. (From the Wikpedia article Edema.)

Download PDF containing detailed information.

Recent Publications on Edema:
Evaluation of laryngeal findings in users of inhaled steroids. The objective of the prospective study is to examine the laryngeal changes...	13th November, 2009	Department of Otorhinolaryngology, Istanbul Goztepe Training and Research	Eur Arch Otorhinolaryngol. 2009 Nov 12. DOI Direct Link
The Histamine H(4) Receptor Mediates Inflammation and Pruritus in Th2-Dependent Dermal Inflammation. The role of histamine H(4) receptor (H(4)R) was investigated in a T-helper...	13th November, 2009	Department of Immunology, Johnson & Johnson Pharmaceutical Research &	J Invest Dermatol. 2009 Nov 12. DOI Direct Link
Glaucoma Tube Shunt Implantation Through the Ciliary Sulcus in Pseudophakic Eyes With High Risk of Corneal Decompensation. PURPOSE: To summarize our clinical experience with implanting Baerveldt...	13th November, 2009	*Beaumont Eye Institute section signBeaumont Research Institute, William	J Glaucoma. 2009 Nov 10. DOI Direct Link
Cardiac Efficiency Improvement after Slow Continuous Ultrafiltration Is Assessed by Beat-to-Beat Minimally Invasive Monitoring in Congestive Heart Failure Patients: A Preliminary Report. Background: We have evaluate the effect of slow continuous ultrafiltration...	13th November, 2009	Department of Cardiac and Vascular Sciences, University of Florence,	Blood Purif. 2009 Nov 12;29(1):44-51. DOI Direct Link
GIANT LYMPHOCELE AFTER RENAL TRANSPLANTATION. CASE REPORT AND BIBLIOGRAPHIC REVIEW. OBJECTIVES: To report the case and iconography of a lymphocele after renal...	13th November, 2009	Department of Urology. Hospital Juan Canalejo. La Coruna. Spain.	Arch Esp Urol. 2009 Oct;62(8):667-671.
→View more research publications.

Press Releases About Edema:
ThromboGenics NV - Q3 2009 Business Update	4th November, 2009		LEUVEN, Belgium, November 4 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is
Regeneron Reports Third Quarter 2009 Financial and Operating Results	3rd November, 2009	Regeneron Pharmaceuticals, Inc.	TARRYTOWN, N.Y., Nov. 3 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the third quarter of 2009. The Company reported a
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases	2nd November, 2009	Quark Pharmaceuticals, Inc.	FREMONT, Calif., Nov. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)
Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications	26th October, 2009	Reportlinker	NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Immunotherapies and Vaccines for Nontraditional
Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene	26th October, 2009	Quark Pharmaceuticals, Inc.	FREMONT, Calif. Oct. 26 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today

BioNews Results for Edema:
Nov 12 N Engl J Med letter	New England Journal of Medicine:  Nov 13 2009 5:25PM Matching: edema
pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009	Pharma Live:  Nov 13 2009 9:39PM Matching: edema
Researchers detail lung damage in fatal cases	New England Journal of Medicine:  Nov 13 2009 5:25PM Matching: edema
OD-OS earns FDA Approval for its NAVILAS navigated laser therapy system	Open PR:  Nov 12 2009 9:16AM Matching: edema
pSivida Corp. Reports Results for the First Quarter Ended September 30, 2009	Yahoo! Canada:  Nov 12 2009 11:26PM Matching: edema
Promote your company here: BioNewsCast - Press Release Distribution	→View more news.

Edema Clinical Trials:
Effect of Choline Fenofibrate (SLV348) on Macular Edema

Edema Patents:
US Patent No.	Title
7610074	Multi-functional plasmon-resonant contrast agents for optical coherence tomography
7611897	AP1 amine oxidase variants
7612035	Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
7612047	Degradation-resistant mononucleoside phosphate compounds
7612060	Triazoles and methods of use
→View more patents.

Companies working in the area of Edema from Bioportfolio's Biocorporate database :
Company Name
Diapulse The body is as much electrical as it is chemical.... Diapulse â is a new approach for wound care. The proprietary Diapulse Technology is a safe, cost-effective treatment of post-operative edema and... www.diapulse.com        View full profile
Aciont Inc. AciontTM Inc. endeavors to become the world leader in commercializing localized, non-invasive and controlled release back-of-the-eye therapeutics for sight threatening diseases. Our name Aciont (... www.aciont.com/        View full profile
Aircast Founded in the early 70's Aircast exists because of a lucky break — that's if you can call getting a segmental tibial fracture while skiing being lucky. After months in a plaster cast Glenn Johnson... www.AIRCAST.COM/        View full profile
→View more Edema related companies.

BioPortfolio Ltd. offers e-mail and postal lists for Edema scientists - we have details of around 8663 individuals working on Edema .